Here, data aggregated by epidemiological week and country were used to calculate the proportions of infections caused by the Omicron variant. For analyses reported in the Results section, two …
In this figure, we present the numbers of observations included in analyses in the different subsections of the Results section.
Age distributions (x-axes show proportions; y-axes, age groups) when Omicron variant relative frequency was below 10% (blue bars) and when the frequency was 90% or higher (red bars). Data from …
Frequencies of the five most common symptoms (A) and comorbidities (B) during the pre-Omicron (blue bars) and Omicron (red bars) periods. 95% confidence intervals are shown. Note that South Africa …
In each panel, the x-axis shows countries (ISO3 codes are presented), with different periods represented by circles with different colours (blue circles for the pre-Omicron period; red circles, for …
The same structure of Figure 1 was used but different cut-off frequencies for Omicron variant were applied: in (A), the lower and upper threshold frequencies were 10% and 80%; in (B), these …
95% confidence intervals are also shown. In (A), data from individuals aged between 18 and 60 years are shown; and (B) shows the same information for individuals older than 60 years. Data from …
Only data from countries with at least 50 observations with information on previous vaccination during both study periods defined by Omicron variant frequency are shown. In each panel, the x-axis …
Data from different countries are presented in different panels; x-axes show epidemiological weeks since the first epidemiological week of 2020. As in Figure 1, continuous black lines represent …
In each panel, the x-axis shows countries, with different periods represented by circles with different colours (blue circles for the pre-Omicron period; red circles, for period after Omicron …
In each panel, the x-axis shows countries, with different periods represented by circles with different colours (blue circles for the pre-Omicron period; red circles, for the Omicron period). 95% …
The legend of that figure applies to this figure, except that instead of referring to time periods, the figure shows data for Delta and Omicron variants. Only countries with at least 10 observations …
The legend of that figure applies to this figure, except that instead of referring to time periods, the figure shows data for Delta and Omicron variants. Only countries with at least 10 observations …
The legend of that figure applies to this figure, except that instead of referring to time periods, the figure shows data for Delta and Omicron variants. Only countries with at least 10 observations …
The legend of that figure applies to this figure, except that instead of referring to time periods, the figure shows data for Delta and Omicron variants. Only countries with at least 10 observations …
The legend of that figure applies to this figure. Here, the upper threshold frequency used to define Omicron variant dominance was 80% rather than 90%.
The legend of that figure applies to this figure. Here, the upper threshold frequency used to define Omicron variant dominance was 80% rather than 90%.
The legend of that figure applies to this figure. Here, the upper threshold frequency used to define Omicron variant dominance was 80% rather than 90%.
The legend of that figure applies to this figure. Here, the upper threshold frequency used to define Omicron variant dominance was 80% rather than 90%.
Data for period-country combinations with less than 10 observations are not presented. Data on vaccination status were not available for patients from Saudi Arabia.
pre-Omicron period | Omicron period | |||
---|---|---|---|---|
Country | % Vaccinated | Total N | % Vaccinated | Total N |
Brazil | 84.6 | 13 | 87.9 | 33 |
Canada | 32.2 | 59 | 57.3 | 686 |
Colombia | 42.1 | 19 | - | <10 |
Estonia | - | <10 | ||
Germany | - | <10 | - | <10 |
India | 34.8 | 23 | 84.8 | 33 |
Malaysia | 79.3 | 29 | 80.0 | 10 |
Nepal | 25.3 | 190 | 39.3 | 183 |
Netherlands | 60.0 | 60 | 51.0 | 51 |
New Zealand | 5.9 | 34 | - | <10 |
Norway | - | <10 | 82.2 | 45 |
Philippines | 78.6 | 14 | - | <10 |
Portugal | - | <10 | - | <10 |
Romania | - | <10 | 78.6 | 98 |
South Africa | 15.1 | 1605 | 27.9 | 24752 |
Spain | 45.0 | 20 | 70.9 | 55 |
United Kingdom | 65.4 | 6865 | 70.3 | 7846 |
United States of America | - | <10 | - | <10 |
Argentina | - | <10 | ||
Australia | - | <10 | ||
Indonesia | - | <10 | ||
Israel | 54.5 | 11 | ||
Kuwait | 66.7 | 18 | ||
Turkey | 74.1 | 27 |
Results of multivariate logistic models, with random intercepts for countries, on 14-day fatality risk are presented. Different models were fit that included different variables. Model III adjusts …
Model | I | II | III | IV |
---|---|---|---|---|
Number of observations | 94,077 | 39,950 | 26,728 | 56,329 |
Odds ratio (95% CI) | Odds ratio (95% CI) | Odds ratio (95% CI) | Odds ratio (95% CI) | |
Variables | ||||
Omicron period* | 0.65 (0.62–0.69) | 0.67 (0.61–0.75) | 0.68 (0.60–0.77) | 0.64 (0.59–0.69) |
Sex (male) | 1.32 (1.26–1.38) | 1.33 (1.23–1.43) | 1.36 (1.24–1.49) | 1.33 (1.25–1.42) |
Age | ||||
Older than 60 years | Reference | Reference | Reference | Reference |
Aged between 18 and 60 years | 0.26 (0.25–0.27) | 0.24 (0.22–0.26) | 0.27 (0.25–0.30) | 0.30 (0.27–0.32) |
Younger than 18 years | 0.06 (0.05–0.07) | 0.06 (0.05–0.07) | 0.07 (0.05–0.09) | 0.06 (0.05–0.08) |
Previous vaccination | - | 0.60 (0.55–0.65) | 0.53 (0.48–0.59) | 0.59 (0.54–0.65) |
Comorbidities | ||||
Hypertension | - | - | 1.29 (1.16–1.42) | 1.26 (1.17–1.35) |
Diabetes | - | - | 1.22 (1.09–1.38) | 1.22 (1.12–1.32) |
Chronic cardiac disease | - | - | 1.50 (1.31–1.71) | 1.51 (1.39–1.65) |
Odds ratio in univariate analysis 0.65 (0.61–0.69) (N=94,524).
Country | Number of records |
---|---|
South Africa | 69766 |
United Kingdom | 55049 |
Pakistan | 929 |
Canada | 919 |
Nepal | 504 |
Laos | 456 |
India | 409 |
Romania | 166 |
Saudi Arabia | 151 |
Spain | 151 |
Netherlands | 134 |
Malaysia | 90 |
Norway | 67 |
Turkey | 57 |
Brazil | 54 |
Colombia | 52 |
New Zealand | 46 |
Kuwait | 35 |
United States | 32 |
Philippines | 26 |
Ghana | 21 |
Ireland | 20 |
Israel | 17 |
Italy | 12 |
Estonia | 7 |
Australia | 7 |
Indonesia | 6 |
Portugal | 5 |
Germany | 4 |
Argentina | 4 |
Note that this information was not systematically recorded in South Africa, and for this reason data from that country are not included in this table.
Symptoms | Yes | No | Missing data |
---|---|---|---|
Any cough | 20431 | 13726 | 25273 |
Fever | 16045 | 19465 | 23920 |
Headache | 3896 | 28398 | 27136 |
Confusion | 5960 | 28548 | 24922 |
Seizures | 570 | 33424 | 25436 |
Sore throat | 2394 | 29353 | 27683 |
Runny nose | 1639 | 30279 | 27512 |
Vomiting | 6956 | 27734 | 24740 |
Wheezing | 2042 | 31191 | 26197 |
Diarrhoea | 4418 | 29989 | 25023 |
Chest pain | 5488 | 28732 | 25210 |
Conjunctivitis | 106 | 32606 | 26718 |
Myalgia | 3686 | 28195 | 27549 |
Rash | 476 | 32877 | 26077 |
Fatigue | 11339 | 22150 | 25941 |
Ageusia | 1682 | 28341 | 29407 |
Inability to walk | 252 | 3797 | 55381 |
Anosmia | 1393 | 29040 | 28997 |
Shortness of breath | 20490 | 14030 | 24910 |
Lymphadenopathy | 145 | 32795 | 26490 |
In this table, data from all countries are included.
Comorbidities | Yes | No | Missing data |
---|---|---|---|
Liver disease | 1786 | 40992 | 86418 |
Diabetes | 12956 | 68743 | 47497 |
Chronic cardiac disease | 13546 | 73423 | 42227 |
Hypertension | 32052 | 57401 | 39743 |
Current smoking | 5090 | 26674 | 97432 |
COPD | 9304 | 77794 | 42098 |
Active TB | 1579 | 45731 | 81886 |
Asthma | 8720 | 79175 | 41301 |
Chronic kidney disease | 8441 | 78453 | 42302 |
Malignant neoplasm | 5062 | 81465 | 42669 |
Dementia | 4646 | 38530 | 86020 |
HIV | 5925 | 79121 | 44150 |
Chronic neurological disorder | 5615 | 37740 | 85841 |
Obesity | 5723 | 45367 | 78106 |
Potential limitation | Likely impact on analyses |
---|---|
Population-level data come from a range of sources in each country, and for most samples it is not possible to determine whether patient was hospitalised or was a community (mild) case | If different variants are associated with different severities upon infection and if a large fraction of samples used in the estimation of population-level frequency of variants are from community cases, then it is possible that this frequency does not fully represent the frequency in the hospitalised population. In particular, if Omicron variant infection is linked to lower risk of hospitalisation, as previous studies suggest, it is possible that even during periods when community-level frequency of Omicron variant was high, the frequency of Omicron variant in the hospitalised population might have been relatively low. |
Use of country-level data, rather than data on variant frequency in the catchment areas of clinical centres contributing data | If Omicron variant spreads asynchronously in a country, with some regions reaching high relative frequency faster than others, it is possible that country-level data, rather than data at a finer geographical level, might not reflect Omicron variant frequency in the population from which patients were recruited. |
Delay between infection, onset of symptoms and hospitalisation | Depending on the data source used to define population-level frequency of variants, if clinical samples were obtained early during the infection, hospitalised cases might only have the same variant composition after a time lag, corresponding to average time from infection, or onset of symptoms, to hospital admission. |
Omicron emergence | |||
---|---|---|---|
Country | Before 10% | After 90% | Total |
South Africa | 4180 | 51929 | 56109 |
United Kingdom | 18124 | 26479 | 44603 |
Canada | 61 | 763 | 824 |
Nepal | 197 | 204 | 401 |
India | 89 | 212 | 301 |
Netherlands | 60 | 65 | 125 |
Saudi Arabia | 2 | 121 | 123 |
Romania | 1 | 100 | 101 |
Spain | 21 | 56 | 77 |
Malaysia | 42 | 11 | 53 |
Norway | 5 | 45 | 50 |
Brazil | 15 | 33 | 48 |
New Zealand | 34 | 6 | 40 |
Colombia | 26 | 5 | 31 |
Turkey | 0 | 27 | 27 |
Philippines | 16 | 5 | 21 |
United States of America | 14 | 7 | 21 |
Kuwait | 0 | 19 | 19 |
Ghana | 4 | 15 | 19 |
Ireland | 14 | 3 | 17 |
Israel | 0 | 14 | 14 |
Australia | 0 | 6 | 6 |
Portugal | 3 | 2 | 5 |
Indonesia | 1 | 4 | 5 |
Germany | 2 | 2 | 4 |
Italy | 3 | 0 | 3 |
Argentina | 0 | 3 | 3 |
Estonia | 1 | 0 | 1 |
Only countries with 10 or more observations in both study periods are shown.
Before 10% | After 90% | |||||
---|---|---|---|---|---|---|
Country | Median | Q1 | Q3 | Median | Q1 | Q3 |
Brazil | 59 | 50 | 70 | 55 | 48 | 70 |
Canada | 63 | 50 | 71 | 62 | 35 | 76 |
Spain | 68 | 63 | 75 | 76 | 59 | 84 |
United Kingdom | 66 | 48 | 78 | 67 | 38 | 81 |
India | 63 | 47 | 72 | 70 | 60 | 76 |
Malaysia | 63 | 52 | 68 | 59 | 55 | 63 |
Netherlands | 74 | 64 | 80 | 70 | 55 | 77 |
Nepal | 63 | 42 | 77 | 64 | 42 | 75 |
South Africa | 45 | 30 | 62 | 41 | 27 | 63 |
For country-time period combinations with less than 10 observations, numbers are not presented.
Before 10% | After 90% | |||||
---|---|---|---|---|---|---|
Country | COVID-19 as reason (N) | COVID-19 as reason (%) | Total | COVID-19 as reason (N) | COVID-19 as reason (%) | Total |
Australia | - | - | <10 | |||
Argentina | - | - | <10 | |||
Brazil | 14 | 100 | 14 | 32 | 96.7 | 33 |
Canada | 12 | 52.2 | 23 | 514 | 67.5 | 761 |
Colombia | 2 | 7.7 | 26 | - | - | <10 |
Germany | - | - | <10 | - | - | <10 |
Ghana | - | - | <10 | |||
India | 0 | 0 | 12 | 2 | 8.3 | 24 |
Indonesia | - | - | <10 | |||
Israel | 8 | 66.7 | 12 | |||
Kuwait | 0 | 0 | 18 | |||
Malaysia | - | - | <10 | - | - | <10 |
Nepal | - | - | <10 | 0 | 0 | 15 |
Netherlands | 49 | 81.7 | 60 | 39 | 61.9 | 63 |
New Zealand | 30 | 90.9 | 33 | - | - | <10 |
Norway | - | - | <10 | 34 | 75.5 | 45 |
Philippines | 16 | 100 | 16 | - | - | <10 |
Romania | - | - | <10 | 100 | 100 | 100 |
Saudi Arabia | - | - | <10 | 68 | 68.7 | 99 |
South Africa | 1433 | 71.1 | 2015 | 18306 | 69.0 | 26512 |
Spain | 11 | 64.7 | 17 | 37 | 66.1 | 56 |
Turkey | 27 | 100 | 27 | |||
USA | 0 | 0 | 11 | - | - | <10 |
Only countries with at least 10 patients in each study period are included.
Before 10% | After 90% | |||
---|---|---|---|---|
Country | % with one or more comorbidities | Total | % with one or more comorbidities | Total |
Brazil | 78.6 | 14 | 81.8 | 33 |
Canada | 76.7 | 60 | 74.2 | 760 |
India | 44.9 | 89 | 56.9 | 209 |
Malaysia | 64.3 | 42 | 72.7 | 11 |
Nepal | 46.2 | 197 | 55.4 | 204 |
Netherlands | 86.7 | 60 | 78.5 | 65 |
South Africa | 53.9 | 3170 | 44.7 | 37412 |
Spain | 76.2 | 21 | 76.8 | 56 |
United Kingdom | 86.5 | 11820 | 84.6 | 21501 |
Only countries with at least 10 patients in each study period are included.
Before 10% | After 90% | |||
---|---|---|---|---|
Country | % with one or more symptoms | Total | % with one or more symptoms | Total |
Brazil | 100.0 | 14 | 100.0 | 32 |
Canada | 91.7 | 60 | 91.6 | 754 |
India | 28.1 | 89 | 18.6 | 210 |
Malaysia | 64.3 | 42 | 90.9 | 11 |
Nepal | 97.0 | 197 | 86.3 | 204 |
Netherlands | 96.7 | 60 | 96.9 | 65 |
Spain | 100.0 | 21 | 87.5 | 56 |
United Kingdom | 97.4 | 11104 | 89.3 | 16157 |
Only countries with 10 or more observations in both study periods are presented.
pre-Omicron period | Omicron period | ||||||
---|---|---|---|---|---|---|---|
Country | Median | Q1 | Q3 | Median | Q1 | Q3 | |
Canada | 10 | 6 | 21 | 10 | 5 | 18 | |
United Kingdom | 11 | 6 | 19 | 11 | 6 | 19 | |
India | 6 | 3 | 8 | 7 | 3 | 12 | |
Nepal | 6 | 5 | 12 | 4 | 2 | 8 | |
South Africa | 6 | 2 | 12 | 5 | 2 | 10 | |
Results of a Cox proportional hazards model, stratified by country, on time to death in the first 28 days since hospital admission or onset of symptoms, which happened latest, are shown in the …
Hazard ratio | Subhazard ratio | ||
---|---|---|---|
Variables | |||
Omicron period | 0.77 (0.71–0.84) | 0.79 (0.73–0.84) | |
Sex (male) | 1.24 (1.17–1.32) | 1.32 (1.24–1.40) | |
Age | |||
Older than 60 years | Reference | ||
Aged between 18 and 60 years | 0.41 (0.38–0.44) | 0.26 (0.24–0.28) | |
Younger than 18 years | 0.13 (0.11–0.17) | 0.06 (0.04–0.07) |
Only countries with at least 10 observations for Delta and Omicron variants are listed. Note that other countries had limited numbers for both or one of the two variants.
Country | Delta | Omicron |
---|---|---|
Canada | 26 | 303 |
Netherlands | 12 | 52 |
Norway | 15 | 22 |
South Africa | 17 | 720 |
Spain | 10 | 16 |